12,107 Shares in Stryker Corporation $SYK Purchased by Burnham & Co LLC

Key Points

• Burnham & Co. LLC purchased 12,107 Stryker shares worth approximately $3.8 million, making the medical technology company 3.1% of the fund’s holdings. Institutional investors collectively own about 77.1% of SYK.
• Stryker’s latest quarter exceeded expectations, with EPS of $3.69 and revenue of $6.59 billion, up 9.4% year over year. The company maintained fiscal 2026 EPS guidance of $14.95–$15.10 and declared a quarterly dividend of $0.88.
• Analysts maintain a broadly positive “Moderate Buy” consensus with an average price target of $386.28, but several firms have lowered targets following execution concerns. Insiders have also sold 665,370 shares worth roughly $216.2 million over the past 90 days.

Burnham & Co LLC bought a new position in Stryker Corporation (NYSE:SYK - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 12,107 shares of the medical technology company's stock, valued at approximately $3,812,000. Stryker comprises 3.1% of Burnham & Co LLC's holdings, making the stock its 11th largest holding.

Several other institutional investors also recently modified their holdings of the business. Sankala Group LLC bought a new stake in Stryker during the fourth quarter valued at $26,000. United Financial Planning Group LLC bought a new position in Stryker in the 3rd quarter worth about $27,000. Godfrey Financial Associates Inc. purchased a new stake in shares of Stryker in the 4th quarter valued at about $26,000. Atlas Capital Advisors Inc. bought a new stake in shares of Stryker during the 4th quarter valued at about $27,000. Finally, Gables Capital Management Inc. purchased a new position in shares of Stryker during the second quarter worth about $25,000. 77.09% of the stock is owned by institutional investors.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here's Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Stock Performance

Shares of Stryker stock opened at $329.86 on Friday. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The firm's 50-day moving average is $326.99 and its 200 day moving average is $332.64. The stock has a market cap of $126.52 billion, a price-to-earnings ratio of 34.18, a PEG ratio of 2.09 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion during the quarter, compared to analysts' expectations of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts anticipate that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker's payout ratio is 36.48%.

Insider Buying and Selling at Stryker

In other news, insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company's stock, valued at $2,088,423. This represents a 11.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the business's stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company's stock, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 665,370 shares of company stock worth $216,238,501. Insiders own 4.60% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on SYK shares. Needham & Company LLC reduced their target price on Stryker from $454.00 to $418.00 and set a "buy" rating on the stock in a research note on Friday, May 1st. Citizens Jmp dropped their price target on Stryker from $440.00 to $400.00 and set a "market outperform" rating for the company in a research note on Monday, August 3rd. Evercore set a $350.00 price objective on Stryker in a research report on Monday, July 6th. JPMorgan Chase & Co. decreased their price objective on Stryker from $400.00 to $350.00 and set an "overweight" rating on the stock in a report on Friday, July 31st. Finally, Wolfe Research downgraded Stryker from an "outperform" rating to a "peer perform" rating in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons' offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source